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Abstract
IMPORTANCE Acquired and heritable traits are associated with dementia risk; however, how these
traits are associated with age at symptomatic onset (AAO) of Alzheimer disease (AD) is unknown.
Identifying the associations of acquired and heritable factors with variability in intergenerational AAO
of AD could facilitate diagnosis, assessment, and counseling of the offspring of parents with AD.
OBJECTIVE To quantify the associations of acquired and heritable factors with intergenerational
differences in AAO of AD.
DESIGN, SETTING, AND PARTICIPANTS This nested cohort study used data from the Knight
Alzheimer Disease Research Center that included community-dwelling participants with
symptomatic AD, parental history of dementia, and available DNA data who were enrolled in
prospective studies of memory and aging from September 1, 2005, to August 31, 2016. Clinical,
biomarker, and genetic data were extracted on January 17, 2017, and data analyses were conducted
from July 1, 2017, to August 20, 2019.
MAIN OUTCOMES AND MEASURES The associations of acquired (ie, years of education; body mass
index; history of cardiovascular disease, hypertension, hypercholesterolemia, diabetes, active
depression within 2 years, traumatic brain injury, tobacco use, and unhealthy alcohol use; and
retrospective determination of AAO) and heritable factors (ie, ethnicity/race, paternal or maternal
inheritance, parental history of early-onset dementia, APOE ε4 allele status, and AD polygenic risk
scores) to intergenerational difference in AAO of AD were quantified using stepwise forward
multivariable regression. Missense or frameshift variants within genes associated with AD
pathogenesis were screened using whole-exome sequencing.
RESULTS There were 164 participants with symptomatic AD, known parental history of dementia,
and available DNA data (mean [SD] age, 70.9 [8.3] years; 90 [54.9%] women) included in this study.
Offspring were diagnosed with symptomatic AD a mean (SD) 6.1 (10.7) years earlier than their parents
(P < .001). The adjusted R2 for measured acquired and heritable factors for intergenerational
difference in AAO of AD was 0.29 (F8,155 = 9.13; P < .001). Paternal (β = −9.52 [95% CI, −13.79 to
−5.25]) and maternal (β = −6.68 [95% CI, −11.61 to −1.75]) history of dementia, more years of
education (β = −0.58 [95% CI −1.08 to −0.09]), and retrospective determination of AAO (β = −3.46
[95% CI, −6.40 to −0.52]) were associated with earlier-than-expected intergenerational difference in
AAO of AD. Parental history of early-onset dementia (β = 21.30 [95% CI, 15.01 to 27.59]), presence
of 1 APOE ε4 allele (β = 5.00 [95% CI, 2.11 to 7.88]), and history of hypertension (β = 3.81 [95% CI,
0.88 to 6.74]) were associated with later-than-expected intergenerational difference in AAO of AD.
Missense or frameshift variants within genes associated with AD pathogenesis were more common
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Abstract (continued)
in participants with the greatest unexplained variability in intergenerational AAO of AD (19 of 48
participants [39.6%] vs 26 of 116 participants [22.4%]; P = .03).
CONCLUSIONS AND RELEVANCE Acquired and heritable factors were associated with a substantial
proportion of variability in intergenerational AAO of AD. Variants in genes associated with AD
pathogenesis may contribute to unexplained variability, justifying further study.
JAMA Network Open. 2019;2(10):e1913491. doi:10.1001/jamanetworkopen.2019.13491
Introduction
After age, genetic factors are the second-greatest factors associated with risk of symptomatic
Alzheimer disease (AD). Therefore, it is not surprising that offspring of parents with dementia have
an increased lifetime risk of symptomatic AD,1,2 with the greatest risk experienced by those with a
maternal history or with 2 affected parents3-5 and those who inherited 1 or 2 copies of the APOE
(OMIM 107741) ε4 allele.6 Prior studies have suggested that disease expression may change across
generations, with the offspring of affected parents experiencing an earlier age at symptomatic onset
(AAO) of AD.1,2,7,8 A 2017 study by Livingston et al9 suggested that the cumulative effects of acquired
and heritable traits are associated with intergenerational dementia risk. However, how these traits are
associated with AAO of AD is unknown, to our knowledge. Identifying the associations of acquired and
heritable factors with variability in intergenerational AAO of AD may facilitate diagnosis, assessment, and
counseling of offspring of affected parents who have a high risk of developing dementia and high
interest in knowing their dementia risk.10 These same factors may also be exploited to delay onset of
AD and improve patient outcomes.
We evaluated the associations of well-characterized acquired and heritable risk and protective
factors for AD to variability in intergenerational AAO in people whose parents had dementia and who
were enrolled in Knight Alzheimer Disease Research Center (ADRC) of Washington University in St
Louis, St Louis, Missouri, longitudinal studies of memory and aging. We hypothesized that measured
factors would be associated with a significant proportion of observed variability. Furthermore, we
considered whether offspring with the greatest unexplained variability might have additional genetic
variants that were associated with variability in intergenerational AAO of AD. In this way, we used
variability in intergenerational AAO as a putative endophenotype to identify individuals who may
have genetic variants that accelerate or delay onset of AD.
Methods
Participant Identification and Recruitment
The Knight ADRC recruits and longitudinally assesses community-dwelling adults older than 45 years
via prospective studies of memory and aging. Eligible participants may be asymptomatic or have
early symptoms of AD. All participants are required to have an observant informant who can provide
collateral history and are asked to participate in core study procedures, including longitudinal clinical
assessments, neuropsychological testing, neuroimaging, and biofluid biomarker studies.
Participants in this study were enrolled within specific longitudinal Knight ADRC studies (ie,
Adult Children Study or Healthy Aging and Senile Dementia Project) from December 4, 1979, to
August 31, 2016, and assessed according to standard Knight ADRC practices. Research nurses or
social workers reviewed medical and family history at enrollment and subsequent visits. Parental
AAO of dementia was reported by study participants and verified with study partners and family
members. All participants were assessed annually by experienced clinicians using a semistructured
interview with a knowledgeable collateral source and the symptomatic individual and by detailed
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neurological examination. A clinical diagnosis of dementia was considered by study clinicians at the
conclusion of each assessment, integrating results from the clinical assessment and bedside
measures of cognitive function (detailed elsewhere11). Dementia diagnostic criteria conformed to
National Institute on Aging–Alzheimer’s Association Work Group recommendations.12 Dementia
stages were classified using the global Clinical Dementia Rating and assigned by qualified clinicians in
accordance with established scoring rules.13 Participants from families with known disease-causing
APP (OMIM 104760), PSEN1 (OMIM 104311), and PSEN2 (OMIM 600759) mutations were excluded.
Participants with a clinical diagnosis of symptomatic AD and reported parental history of
dementia were selected through review of the Knight ADRC database. To ensure uniform collection
and reporting of variables of interest for subsequent analyses, the data set was limited to participants
who were evaluated after the Uniform Data Set version 1.2 was introduced on September 1, 2005,14
and from whom DNA data were available. In a few instances, the parents of participants were also
longitudinally studied, providing an opportunity to compare reported and observed parental AAO. All
participants or their delegates provided written informed consent or assent to the use of clinical and
genetic information for research purposes. The Washington University School of Medicine
Institutional Review Board approved all study procedures. Clinical, biomarker, and genetic data were
extracted on January 17, 2017. Data were analyzed from July 1, 2017, to August 20, 2019. Results were
reported in accordance with the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline for cohort studies.
Data Collection and Analyses
Participants self-reported Hispanic or Latino ethnicity and race (ie, white, African American,
American Indian, Alaskan Native, Native Hawaiian or other Pacific Islander, Asian, other, or
unknown). Acknowledging the putative associations of ethnicity and race to differences in AD,1
reported African American ancestry, the minority racial group most commonly represented in our
cohort, was included in multivariable analyses. Lifetime health history was obtained from
participants and collateral sources at each assessment, including questions assessing interval health,
medication use, and personality or behavioral changes (including mood). Participants’ weight and
height were measured at each visit, and body mass index was derived, calculated as weight in
kilograms divided by height in meters squared. When multiple assessments were completed,
variables measured at the clinical assessment closest to the time of dementia diagnosis (Clinical
Dementia Rating 0.5) were used in analyses. Information concerning the prevalence and severity
of obstructive sleep apnea was not collected as a part of the Uniform Data Set until 201615; therefore,
obstructive sleep apnea was not considered as a variable. A detailed description of variables is
provided in eAppendix 1 in the Supplement.
For participants who did not have symptoms of dementia at enrollment, AAO was prospectively
defined as the age when the global Clinical Dementia Rating was 0.5 or higher. For participants who
had symptomatic AD at enrollment, AAO was retrospectively determined through an interview with
a reliable collateral source. The difference in AAO of AD between parent and offspring was derived
for each participant-parent dyad by subtracting parental AAO from participant AAO. When both
parents were affected, we used the mean parental AAO to determine the difference in AAO. In this
way, we derived a continuous measure of disparity in intergenerational AAO of AD, identifying
participants with earlier-than-expected (negative difference in AAO) and later-than-expected
(positive difference in AAO) AAO of AD.
Cerebrospinal fluid (CSF) measures of amyloid-β peptide 42, total tau, and phosphorylated tau
181,16 or carbon 11–labeled Pittsburgh compound B or florbetapir amyloid positron emission
tomography retention17,18 were obtained from patients for whom such data were available. Genome-
wide association study data were quality controlled and imputed as previously reported.19 A
weighted polygenic risk score (PRS) for AAO of AD was generated for the same participants,19-21
excluding APOE ε allele status, which was included in multivariable analyses. Known dementia-
associated and novel genetic variants were screened in all participants within relevant genes (eg,
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PSEN1, PSEN2, APP, TREM2 [OMIM 605086], PLD3 [OMIM 615698], MAPT [OMIM 157140], C9orf72
(OMIM 614260) and GRN [OMIM 607485]) using whole-exome sequencing. Databases detailing genes
associated with genetic variants associated with AD, frontotemporal dementia, and Parkinson disease
were used to annotate the whole-exome sequencing data, defining known pathogenic variants (ie,
AD&FTD Mutation Database, Parkinson Disease Mutation Database).22 These databases are updated
continuously with pathogenic and nonpathogenic genetic variants that occur in the coding regions
of genes associated with AD, frontotemporal dementia, and Parkinson disease and are reported in the
literature, reported at scientific meetings, or directly submitted. Genetic analyses and AD biomarker
measures are detailed in eAppendix 2 in the Supplement.
Statistical Analysis
Data were analyzed using SPSS statistical software version 24.0 (IBM). Groupwise differences for
categorical variables were determined using the Fisher exact or Pearson χ2 tests. Continuous
measures were compared using the t test unless otherwise stated. The associations of the
intergenerational difference in AAO of AD (dependent variable) with acquired (ie, years of education;
body mass index; history of cardiovascular disease, hypertension, hypercholesterolemia, diabetes,
active depression within 2 years, traumatic brain injury, tobacco abuse, or unhealthy alcohol use; or
retrospective determination of AAO) and heritable factors (ie, ethnicity/race, paternal or maternal
history of dementia, parental history of early-onset dementia, APOE ε4 allele status, or AD PRS) were
explored using stepwise multivariable linear regression (α = .05 for entry; α = .10 for removal),
controlling for age and sex (forced entry). To assess for collinearity, variables of interest were
included in a linear regression (forced entry) model and variance inflation factor quotients were
computed. Variance inflation factors less than 5 were considered to indicate low probability of
collinearity. Model explanatory power and fit were assessed using the adjusted R2 and analysis of
variance. Residual values were determined on a participant-by-participant basis by subtracting the
expected intergenerational difference in AAO of AD (ie, that predicted from the model) from the
observed intergenerational difference in AAO so that negative residuals identified participants
whose observed intergenerational difference in AAO occurred earlier than expected and positive
residuals participants whose intergenerational difference in AAO of AD occurred later than predicted.
Z scores of residuals were determined, and participants were rank ordered. Participants with
greater-than-expected residuals (ie, highest variability in intergenerational difference in AAO of AD
not associated with measured variables) were defined as those with residuals more than 1 SD below
(risk) or above (resilience) the mean. P values were 2-tailed, and statistical significance was defined
as P less than .05 and Bonferoni corrected where appropriate.
Results
Of 2028 Knight ADRC participants with symptomatic AD, 482 (23.7%) had at least 1 parent with
dementia and reported AAO of AD. Of these, 164 participants (34.0%) were evaluated after 2005,
had DNA available, and were included in this study (Figure 1). The mean AAO of AD among the full
cohort was 70.9 (8.3) years, and 90 (54.9%) were women. At study inclusion, enrolled participants
had completed a mean (SD) of 3.5 (4.6) annual clinical assessments (range, 1-27). Biomarkers were
consistent with AD in 84 of 98 offspring of affected parents (85.7%) for whom biomarker data were
available. No statistically significant differences were found between participants in whom biomarker
data was consistent vs inconsistent with AD as the etiologic cause of dementia (eTable 1 in the
Supplement). Accordingly, all eligible participants were included in analyses, consistent with our
objective to characterize the associations of acquired and heritable factors with intergenerational
variability in AAO among offspring who had received clinical diagnoses of symptomatic AD and their
parents with AD.
Demographic characteristics and clinically relevant symptoms and signs are summarized in
Table 1. The cohort included 102 participants who were symptomatic at the time of study enrollment,
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and their AAO of AD was derived from retrospective report. This group exhibited a younger mean
(SD) AAO than the 62 participants who developed dementia during prospective follow-up and whose
AAO was determined via prospective observation (mean [SD] AAO, 69.1 [7.4] years; range, 46-87
years vs 73.8 [8.9] years; range, 55-96 years; mean difference, −4.7 [95% CI, −7.2 to −2.1]; P < .001),
suggesting that prospective follow-up did not result in earlier recognition of AD onset. Uniquely, the
parents of 11 participants had also participated in longitudinal studies of memory and aging at the
Knight ADRC, with AAO prospectively determined under near-identical protocols. No differences
were observed (mean [SD] AAO, 76.7 [10.0] years; range, 60-95 years) vs retrospectively reported
(mean [SD] AAO, 76.4 [9.8] years; range, 60-92 years) AAO in these parents (Wilcoxon signed rank
test: P = .52; Z = −0.65). The parents of all 11 offspring had received clinical diagnoses of probable AD,
which were confirmed in all 8 parents who underwent autopsy.
In the full cohort, a modest correlation was observed between parental and offspring AAO
(r2 = 0.09; F1,162 = 16.6; P < .001; Figure 2A), with symptoms of AD developing a mean (SD) of 6.1
(10.7) years earlier in offspring compared with their parent (t = −7.3; df = 163; P < .001). A maternal
history of AD was most common, reported by 108 offspring (65.8%). Paternal inheritance was
reported by 35 offspring (21.3%). Both parents were affected for 21 offspring (12.8%). Offspring with
2 affected parents had a mean difference in AAO of 8.0 (95% CI, 2.0-14.0) years earlier than those
Figure 1. Participant Selection
2028 Participants with AD dementia
482 Had ≤1 parent with dementia
164 Assessed since 2005 and had
DNA data available
Difference in AAO was derived
(offspring AAO – parent AAO)
Evaluated factors associated with
difference in AAO
AAO indicates age at symptomatic onset; AD, Alzheimer disease.
Table 1. Participant Characteristics at the Time of Diagnosis With Symptomatic AD
Characteristic No. (%) (N = 164)
AAO of AD, mean (SD) [range], y 70.9 (8.3) [46-96]
Women 90 (54.9)
Education, mean (SD) [range], y 15.4 (2.9) [8-29]
Race/ethnicity
Non-Hispanic white 144 (87.8)
African American 19 (11.6)
Asian 1 (0.6)
APOE ε4 allele carriers 110 (67.1)
1 copy (ε2/4, ε3/4) 89 (54.3)
2 copies (ε4/4) 21 (12.8)
Global Clinical Dementia Rating, median (range) 0.5 (0.5-1.0)
Mini-Mental State Examination Score, mean (SD) [range] 25.0 (3.9) [9-30]
Parental AAO of AD, mean (SD) [range], y
Maternal 77.3 (10.4) [39-102]
Paternal 77.5 (10.7) [47-97]
Abbreviations: AAO, age at symptomatic onset; AD,
Alzheimer disease.
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with just an affected mother (P = .005) and 6.0 years (95% CI, 1.0-13.0) earlier than those with just
an affected father (P = .11) (Figure 2C).
The association of acquired and heritable factors with intergenerational difference in AAO of AD
was quantified using stepwise multivariable linear regression controlling for sex and years of
education. The adjusted R2 of acquired and heritable risk factors for intergenerational variability in
AAO of AD was 0.29 (F8,155 = 9.13; P < .001). Earlier-than-expected intergenerational difference in
AAO was associated with paternal (β = −9.52 [95% CI, −13.79 to −5.25]) and maternal (β = −6.68
[95% CI, −11.61 to −1.75]) history of dementia, having more years of education (β = −0.58 [95% CI,
−1.08 to −0.09]), and retrospective reporting of AAO of AD (β = −3.46 [95% CI, −6.40 to −0.52]).
Later than expected intergenerational difference in AAO was associated with parental history of
early-onset dementia (β = 21.30 [95% CI, 15.01-27.59]), presence of 1 APOE ε4 allele (β = 5.00 [95%
CI, 2.11-7.88]), and history of hypertension (β = 3.81 [95% CI, 0.88-6.74]) (Table 2). Variance inflation
factors were low (range, 1.13-2.32), suggesting that these results were not substantially influenced
by collinearity. The addition of polygenic risk scores specific to AAO of AD did not improve model
performance (adjusted R2 change = 0.001; F1,114 change = 0.11; P = .74). Similar weights were
established when analyses were limited to 84 participants with biomarker-confirmed AD (adjusted
R2 = 0.33; F8,75 = 6.18; P < .001) (eTable 2 in the Supplement). Post hoc analyses considering
participant AAO independent of parental AAO confirmed the expected association of APOE
genotype with AAO of AD (eTable 3 in the Supplement).23,24 APOE ε4/4 carrier status was associated
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with an earlier-than-expected AAO (β = −5.87 [95% CI, −9.25 to −2.50]; P = .001) after controlling for
other acquired and heritable factors (eTable 4 in the Supplement).
We further considered the association of additional unmeasured heritable factors with
unexplained intergenerational variability in AAO of AD using whole-exome sequencing to investigate
for known and potentially novel missense or frameshift variants within genes associated with AD and
AD-related dementia pathogenesis. Sixty-four missense or frameshift variants in PSEN1, PSEN2, APP,
TREM2, PLD3, MAPT, C9orf72 and GRN were identified in 45 offspring (27.4%). Low-frequency coding
variants were detected more frequently in participants with greater unexplained intergenerational
variability in AAO compared with participants with less unexplained variability (19 of 48 offspring
[39.6%] vs 26 of 116 offspring [22.4%]; odds ratio, 2.27 [95% CI, 1.10-4.68]; P = .03), raising the
possibility that these variants were associated with disparity in intergenerational AAO. Only 2 such
variants have previously been associated with an increased risk of AD in the AD&FTD Mutation
Database and Parkinson Disease Mutation Database25: (1) TREM2, p.Arg47His, detected in 2
participants with later-than-expected intergenerational difference in AAO and 1 participant with
earlier-than-expected intergenerational difference in AAO; and (2) PLD3, p.Val232Met, detected in 1
participant with later-than-expected intergenerational difference in AAO. Table 3 lists the variants
discovered in participants with the highest unexplained intergenerational variability in AAO.
Discussion
A parental history of dementia was common in participants with symptomatic AD enrolled in
longitudinal studies of memory and aging at the Knight ADRC , emphasizing the important
associations of family history with AD risk.1,2,4 However, the correlation between AAO in parents and
offspring was modest (r2 = 0.09), in contrast to that observed in a 2014 study by Ryman et al26 of
families with autosomal dominant AD, in whom a substantial proportion of variance in AAO was
Table 2. Results of Multivariate Stepwise Linear Regression of Associations of Measured Factors
With Intergenerational Difference in AAO of Alzheimer Disease
Factor β (95% CI) P Value
Intercept 8.38 (−2.02 to 18.78) .11
Forced entry
Female −1.13 (−4.11 to 1.86) .46
Education, mean (SD), y −0.58 (−1.08 to −0.09) .02
Selected factors
Father affected −9.52 (−13.79 to −5.25) <.001
Mother affected −6.68 (−11.61 to −1.75) .01
Parent with early-onset dementia 21.30 (15.01 to 27.59) <.001
History of hypertension 3.81 (0.88 to 6.74) .01
APOE ε4/2 or ε4/3 5.00 (2.11 to 7.88) .001
Symptomatic at study entry
(retrospective determination of AAO)
−3.46 (−6.40 to −0.52) .02
Excluded factors
Active depression within 2 y −0.12 (NA) .07
History of cardiovascular disease 0.10 (NA) .15
History of tobacco use, >30 pack-yearsa 0.10 (NA) .15
History of hypercholesterolemia −0.11 (NA) .15
Body mass index −0.06 (NA) .35
History of diabetes −0.06 (NA) .37
African American race −0.05 (NA) .45
APOE ε4/4 −0.04 (NA) .60
History of unhealthy alcohol use −0.02 (NA) .74
History of traumatic brain injury −0.01 (NA) .91
Abbreviations: AAO, age at symptomatic onset; NA,
not applicable.
a Calculated as packs of cigarettes used per
day × number of years of use.
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explained by parental AAO (r2 = 0.38). This finding suggests that other factors may modulate AAO
within families without autosomal dominant AD. Indeed, our results suggest that acquired and
heritable factors were associated with a significant proportion of variability in intergenerational AAO
(adjusted R2 = 0.29) with a bias toward an earlier-than-expected intergenerational difference in AAO
in successive generations. This anticipation effect was most apparent in the offspring of 2 affected
parents, which is consistent with prior findings in first-degree relatives of individuals with late-onset
AD.1,2,4,7,8 Beyond parental inheritance, more years of education and retrospective reporting of AAO
were also associated with an earlier-than-expected intergenerational difference in AAO, while APOE
ε4 heterozygosity, family history of early-onset dementia, and late-life hypertension were associated
with later-than-expected intergenerational difference in AAO. If replicated in additional cohorts, this
information may be leveraged to improve estimates of AAO of AD in the offspring of parents with AD,
potentially influencing the timing of dementia screening in clinical and research settings, including
clinical trials of putative AD-modifying therapies designed to prevent or slow the development of
symptomatic AD in presymptomatic individuals.
Somewhat unexpectedly, the presence of an APOE ε4 allele in the offspring of affected parents
was associated with a later-than-expected AAO compared with offspring without APOE ε4. While
these findings appear to conflict with previous reports that suggested an association of APOE ε4
allele status and younger AAO,23,24 it is important to recognize that our study describes the
association of APOE ε4 with intergenerational difference in AAO (ie, the difference between
offspring and parental AAO of AD). In this context, the presence of an APOE ε4 allele in offspring was
associated with a lower difference in AAO, counterbalancing the overall association of an earlier-
than-expected AAO of AD in the offspring of affected parents. Put another way, APOE ε4 allele
carriers exhibited an AAO of AD closer to that reported in their parents than noncarriers after
controlling for other acquired and heritable factors. This association makes sense assuming that
APOE ε4 alleles were inherited from an affected parent and therefore represented a shared dementia
risk factor. Thus, although the presence of APOE ε4 alleles was associated with an earlier-than-
expected AAO vs absence of APOE ε4 alleles, the presence of an APOE ε4 allele is unlikely to explain
the bias toward an earlier-than-expected AAO in offspring of affected parents observed in this study
and others.1,2,7,8
The observed association of parental history of early-onset AD and later-than-expected
intergenerational difference in AAO of AD was also unexpected. Our study design may have
contributed to this association, as participants from families with known autosomal dominant
AD-causing mutations were excluded from our cohort. Thus, parental history of early-onset AD may
have been associated with the combination of deleterious acquired and heritable factors, which were
attenuated in subsequent generations, resulting in an AAO that more closely approximated the mean
or expected AAO (ie, regression toward the mean). Indeed, studies considering first-degree relatives
of individuals with sporadic early-onset dementia did not report a close concordance between AAO
across affected first-degree relatives.27,28 Therefore, in families without known AD-causing
Table 3. Variants Identified Predominantly in Participants With the Greatest Unexplained Intergenerational
Variability in AAO of Alzheimer Diseasea
Z Score of Residuals Gene (Variant) [Amino Acid Position] Mean Residual (Range)b
<−1 SD, earlier-than-expected
offspring AAO
GRN (42429501:G:A) [p.Arg433Gln] −1.63
MAPT (44061123:C:T) [p.Ser318Leu] −1.56 (−2.27 to −0.77)
PLD3 (408758:G:A) [p.Val159Met] −1.38
PSEN1 (73673178:A:G) [p.Glu318Gly] −1.04 (−2.13 to 0.64)
>1 SD, later-than-expected
offspring AAO
GRN (42429835:G:A) [p.Val514Met] 1.49
C9orf72c 1.34
PSEN2 (A346S) 1.32
PLD3 (40877595:G:A) [p.Val232Met] 1.31
APP (V287G) 1.11
Abbreviation: AAO, age at symptomatic onset.
a Residual values from the model were normalized;
high variability was defined as a Z score of residual SD
less than −1 or greater than 1.
b Items without a range were reported in only 1
participant.
c Twenty-nine repeats.
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mutations, a parental history of early-onset dementia may be associated with an increased lifetime
risk of dementia without any association with AAO of AD.29
Several studies have suggested that cumulative years of education may be inversely associated
with dementia risk,9,30-32 an observation thought to reflect cognitive reserve.33 This association is
most consistently demonstrated in individuals with low (eg, <10 years) educational attainment.9 Less
is known concerning the association of dementia risk and education beyond secondary school. To
our knowledge, few studies have considered the association of education with AAO of AD in highly
educated individuals, such as those included in this study. A 1999 study that did report on this
reported a similar association to that observed here, with increasing years of education associated
with an earlier-than-expected AAO.34 This observation may reflect earlier recognition of cognitive
impairment in highly educated individuals. Future studies including participants with a broader range
of educational attainment may yield different results.
The association of late-life hypertension with later-than-expected intergenerational difference
in AAO of AD in our sample suggests that late-life hypertension may delay the symptomatic onset
of AD. This finding may be interpreted as consistent with prior studies reporting an association of low
blood pressure (especially low diastolic blood pressure) with higher risk of dementia in older
individuals.35-38 Alternatively, receiving a diagnosis of late-life hypertension may prompt recognition
and management of other vascular risk factors, mitigating intergenerational differences in AAO
through management of other medical conditions known to be associated with dementia risk.9,39,40
This latter suggestion may explain the lack of association observed in intergenerational difference
in AAO of AD with diabetes, hypercholesterolemia, smoking, and cardiovascular disease in our
cohort. Future studies are needed to clarify the associations of these potentially modifiable risk
factors with AAO of AD and the underlying mechanisms.
Importantly, these associations were found after controlling for retrospective vs prospective
reporting of AAO of AD. Indeed, intergenerational difference in AAO occurred 3.46 (95% CI, −6.40 to
−0.52) years earlier in participants who were symptomatic at study onset vs those who were
diagnosed with dementia during prospective follow-up after controlling for all other variables. This
observation may reflect greater interest in study participation among offspring with an AAO earlier
than that witnessed in their parents, inaccuracy in reporting of AAO, or some combination of these
ascertainment and recall biases. Regardless of the mediators of this association, this finding
emphasizes the importance of controlling for systematic biases that may be associated with AAO of
AD in studies enrolling symptomatic and asymptomatic participants.
Even after accounting for known acquired and heritable factors, most variability in AAO between
parents and offspring was unaccounted for, implying that other factors were associated with intergen-
erational difference in AAO. We explored this possibility further, arguing that offspring with greater un-
explained variability in intergenerational AAO of AD would be more likely to harbor genetic variants that
were associated with intergenerational difference in AAO. Consistent with this hypothesis, low-
frequency missense or frameshift coding variants within relevant genes (eg, PSEN1, PSEN2, APP,
TREM2, PLD3, MAPT, GRN) were more common in offspring with the greatest unexplained variability in
AAO of AD. Although most of the variants discussed in this study have not previously been associated
with AD risk, the associations of these variants with AD pathogenicity should be evaluated in appropri-
ate experimental models and in accordance with existing algorithms.41 Additionally, somatic variants or
recombination or mosaicism within genes associated with AD pathogenesis may also be associated
with intergenerational disparity in AAO, warranting further consideration in participants with greater
unexplained intergenerational variability in AAO.42,43 In this way, measures of variability in intergenera-
tional AAO may serve as putative endophenotypes associated with individuals who may have genetic
variants that accelerate or delay onset of AD.
Limitations
This study has limitations. Unmeasured nonphysiological factors likely contributed to
intergenerational difference in AAO of AD in our cohort, including recall bias in estimates of parental
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AAO. In this context, it is reassuring that reported and observed parental AAOs were similar in the 11
offspring-parent dyads from whom these data were available. The lack of prospective information
regarding parental health history, symptomatic course, and biomarker status presents an additional
limitation. Longitudinal studies incorporating data from parents and offspring are needed to acquire
this information, allowing diagnoses to be applied in accordance with evolving research criteria,44
and the association of shared and discordant acquired and heritable factors (including genetic
variants) with AAO of AD to be determined in parents and offspring. Additionally, we acknowledge
that approximately 15% of individuals from whom data were available did not have biomarker
profiles consistent with AD. These findings are consistent with rates of clinical-pathologic
discordance in other ADRC studies.45 Although the results of multivariable models were similar when
limited to participants with biomarkers consistent with AD, the inclusion of participants without
biomarker evidence of AD may have affected interpretation of study results. These collective
concerns highlight the need to replicate study findings in additional well-characterized, prospectively
evaluated cohort studies before applying these results outside of research settings.
Conclusions
A substantial proportion of intergenerational variability in AAO of AD was associated with measured
acquired and heritable factors in community-dwelling participants enrolled in longitudinal studies
of memory and aging at the Knight ADRC. Variants in genes associated with AD pathogenesis may be
also associated with a proportion of the intergenerational variability in AAO, justifying further study
in appropriate cellular or animal models.
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